CEL-SCI Corp (CVM)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.63+1.24%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CVM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
CVM — debt issuance
Dated 2026-06-16
Entry into a Material Definitive Agreement. On June 14, 2026, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 2,500,000 shares of the Company’s common stock, at an offering price of $1.00 per share (the “Shares”). The Offering closed on June 16, 2026. The gross proceeds from the Offering were $2,500,000 before deducting Placement Agent fees and offering expe…
Why it matters: Smaller losses would show better cash flow and how well the company runs.
Supportive ifOperating losses decrease to less than -$5 million in Q2 2026.
Worry ifOperating losses remain at or exceed -$5.3 million in Q2 2026.
Why it matters: More funding efforts may mean financial trouble or chances for growth.
Watch forA new equity offering or debt issuance over $7.2 million has been announced.
Also watch forThere are no new funding announcements. Financial performance is stable.
Why it matters: Early revenue numbers will show how well the Amarox partnership is doing.
Supportive ifCEL-SCI has its first revenue from Multikine sales in Saudi Arabia.
Worry ifNo revenue came from Multikine sales in Saudi Arabia after six months.
Why it matters: New equity offerings can change how they fund operations and growth. Investors want stability.
Watch forA new equity offering is announced that raises at least $5 million.
Also watch forNo new equity offerings announced. This may mean funding challenges.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$377 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,149 loss on $10,000 · 11.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,088 loss on $10,000 · 90.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This partnership could boost revenue and market reach for Multikine in new regions.
Supportive ifA press release confirms first sales or marketing from the Amarox partnership.
Worry ifNo updates or delays in the partnership rollout or marketing.